| Literature DB >> 32090065 |
Yang Yang1, Qin Chen2, Wen-Ying Yu1, Huan-Huan Zhang1, Yu-Sen Zhong1, Song-Zhao Zhang2, Jia-Feng Wang1, Chen-Huan Yu1.
Abstract
Papillary thyroid carcinoma (PTC) is the most common subtype of differentiated thyroid cancers in Asian coastal cities, where the patients have increased risk of potentially high or excessive iodine intake. Given the high metastasis and recurrence of patients with BRAFV600E mutation, the mortality rate of thyroid cancer has recently shown an upward trend. A variety of therapies, including surgery, radiotherapy, and chemotherapy, have been used to treat thyroid cancer, but these therapies still have limitations, including postoperative complications, drug resistance, poor efficacy, or serious side effects. Recent studies have shown the potential of active ingredients derived from herbal medicine in inhibiting PTC via various cell signaling pathways. Some plant-derived compounds, such as apigenin, genistein, and curcumin, are also known to prevent and treat PTC. This article summarizes the recent advances in the structure-functional impact of anti-PTC active ingredients and their effects on PTC cells and tumor microenvironments with an emphasis on their challenges from basic research to clinical practice.Entities:
Year: 2020 PMID: 32090065 PMCID: PMC7013308 DOI: 10.1155/2020/1340153
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Anti-PTC mechanisms of herbal active ingredients.
| Phytochemicals | Cell lines/patient | Dose ( | Mechanisms | References |
|
| ||||
| EGCG | TPC-1, ARO | 10∼200 | Induce apoptosis via inhibiting EGFR/RAS/ERK pathway | [ |
| FB-2, WRO | 10∼60 | Inhibit EMT | [ | |
|
| ||||
| Resveratrol | TPC-1, BCPAP | 5∼50 | Induce apoptosis and differentiation of CSC | [ |
|
| ||||
| Punicalagin | BCPAP | 12.5∼100 | Induce cell death by triggering ATM-mediated DNA damage; | [ |
|
| ||||
| Curcumin | TPC-1, BCPAP, K1 | 12.5–50 | Induce apoptosis via |
|
| BCPAP | 12.5∼50 | Inhibit invasion and metastasis via | ||
| [ | ||||
| [ | ||||
|
| ||||
| Apigenin | BCPAP | 12.5∼100 | Arrest the cell growth in G2/M phase; induce autophagy via ROS-mediated DNA damage. | [ |
| PCCl3 with BRAFV600E, primary TPC cells | 20 | Synergistic effects with akt inhibitor | [ | |
| Quercetin | BCPAP | 50–75 | Induce apoptosis via inhibiting Hsp90 and caspase-3/parp pathways | [ |
|
| ||||
| Myricetin | SNU-790 | 25∼50 | Induce apoptosis via inhibiting the caspase-dependent mitochondrial pathway | [ |
|
| ||||
| Icariin | SW579, TPC1 | 20–50 | Induce apoptosis via downregulation of miR-625-3p and inactivation of PI3K/Akt and MEK/ERK signaling pathways | [ |
|
| ||||
| Flavokawain B | ARO, WRO, TPC-1 | 3.5–25 | Induce autophagy via regulating AMPK/mTOR pathway | [ |
|
| ||||
| Genistein | BHP10-3, BCPAP, IHH4 | 9.5–300 | Inhibit | [ |
|
| ||||
| Silibinin | TPC-1 | 10–100 | Suppress migration and MMP-9 expression via ERK pathway | [ |
|
| ||||
| Ginsenoside Rg1 | IHH-4, BCPAP | 5–40 | Inhibit cell malignancies by upregulating Cx31 | [ |
|
| ||||
| Ginsenoside Rg3 | TPC-1, BCPAP | 6.25–100 | Inhibit invasion and metastasis via reducing rho GTPase | [ |
|
| ||||
| Capsaicin | BCPAP | 25–100 | Inhibit invasion and metastasis via activation of TRPV1 and subsequently regulating EMT | [ |
|
| ||||
| Berberine | TPC-1 | 10–160 | Induce apoptosis, G0/G1 cell cycle arrest and migration via PI3K/Akt and MAPK pathways | [ |
|
| ||||
| Paclitaxel | PTC patient with SCC component | Weekly 80 mg/m2 | The response rate was 67% and the clinical benefit rate was 100% | [ |
|
| ||||
| Pseudolaric acid B | SW1579 | 1.25–5 | Induce G2/M cell cycle arrest by activating autophagy by decreasing nuclear p53 expression | [ |
|
| ||||
| Shikonin | 8505c, 8305c, FTC133, BCPAP, C643, TPC-1, IHH4, K1, HTori-3 | 3–6 | Induce apoptosis via suppression of ERK/Akt and DNMT1, and activation of p16/Rb and caspase-3-dependent mitochondrial pathways; | [ |
| Inhibit migration and invasion by suppressing EMT and expression of slug and MMP-2, -9, and -14. | [ | |||
|
| ||||
| Allicin | HTh-7 | 10 | Activating autophagy via inactivation of akt and S6 pathways | [ |
EGCG: Epigallocatechin-3-gallate; ATM: ataxia telangiectasia-mutated; ROS: reactive oxygen species; EMT: epithelial-to-mesenchymal transition; CSC: cancer stem cell; ER: endoplasmic reticulum; PTC: papillary thyroid carcinoma; SCC: squamous cell carcinoma; EGFR: epidermal growth factor receptor.
The structure-activity relationship of ginsenosides.
| Basic structure | Compounds | R1 | R2 | R3 | IC50 ( |
|---|---|---|---|---|---|
|
| Protopanaxadiol type (PPD) | ||||
| Rb1 | -Glc2-Glc | -H | -Glc6-Glc | >200 | |
| Rb2 | -Glc2-Glc | -H | -Glc6-Ara (p) | >200 | |
| Rc | -Glc2-Glc | -H | -Glc6-Ara (f) | >200 | |
| Rd | -Glc2-Glc | -H | -Glc | >200 | |
| Rg3 | -Glc2-Glc | -H | -H: 20 (S) | 50 | |
| Rh2 | -Glc | -H | -H: 20 (S) | 45 | |
| CK | -Glc | -H | -Glc6-Ara (p) | 10 | |
| PPD | -H | -H | -H | 80 | |
| Protopanaxatriol type (PPT) | |||||
| Re | -Glc2-Rha | -OH | -Glc | >200 | |
| Rf | -Glc2-Glc | -OH | -H | >200 | |
| Rg1 | -Glc | -OH | -Glc | 40 | |
| Rg2 (S) | -Glc2-Rha | -OH | -H: 20 (S) | >200 | |
| Rh1 | -Glc | -OH | -H | >200 | |
| Rg2 (R) | -Glc2-Rha | -OH | -H: 20 (R) | >200 | |
| PPT | -H | -OH | -H | 70 | |
a: inhibition of thyroid cancer cells (for 48 h).